Received Oct 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
patient received Arexvy without the lyophilized antigen component, only the adjuvant suspension; patient received Arexvy without the lyophilized antigen component, only the adjuvant suspension; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On 14-OCT-2025, the patient received Arexvy. On 14-OCT-2025, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: patient received Arexvy without the lyophilized antigen component, only the adjuvant suspension) and inappropriate dose of vaccine administered (Verbatim: patient received Arexvy without the lyophilized antigen component, only the adjuvant suspension). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 15-OCT-2025 A male patient received Arexvy without the lyophilized antigen component, only the adjuvant suspension. They want to know if they can safely administer another Arexvy shot with the lyophilized antigen and adjuvant suspension correctly reconstituted.